Keith Sullivan Sells 8,452 Shares of Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith Sullivan sold 8,452 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $1.35, for a total value of $11,410.20. Following the sale, the chief executive officer owned 1,524,713 shares in the company, valued at approximately $2,058,362.55. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Neuronetics Price Performance

Shares of Neuronetics stock opened at $1.34 on Friday. The stock has a market cap of $91.78 million, a price-to-earnings ratio of -1.63 and a beta of 0.79. The company has a debt-to-equity ratio of 2.09, a quick ratio of 2.09 and a current ratio of 2.24. The stock has a 50 day moving average price of $1.66 and a 200-day moving average price of $2.23. Neuronetics, Inc. has a one year low of $1.20 and a one year high of $5.92.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey bought a new stake in Neuronetics during the 2nd quarter valued at about $34,000. Raymond James Financial Inc. purchased a new position in shares of Neuronetics during the second quarter worth approximately $37,000. Presidio Capital Management LLC purchased a new position in shares of Neuronetics during the third quarter worth approximately $32,000. Intrua Financial LLC bought a new stake in shares of Neuronetics during the third quarter valued at approximately $33,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of Neuronetics in the third quarter valued at approximately $33,000. 53.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.